Journals / Cukurova Medical Journal / 2021 / Cilt: 46 - Sayı: 4

Comparison of anti-factorXa assay and rotational thromboelastogram in evaluating the efficacy of enoxaparine treatment in patients with acute coronary syndrome without ST- segment elevation

ST segment yükselmesi olmayan miyokard infarktüsü olgularında enoksoparin tedavisinin etkinliğinin değerlendirilmesinde AntiFXa aktivitesi ve tromboleastogram yönteminin karşılaştırılması

Pages
1478–1484
Publication Date
2021-12-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Tromboelastography method can be used in assessment of efficacy of enoxaparin in patients with acute coronary syndrome without ST-Segment elevation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The aim of this study was to compare anti-factor Xa assay and tromboelastogram in evaluation of efficacy of enoxaparin in patients with acute coronary syndrome without ST-segment elevation.
📊
Key Findings & Data:Two blood samples were taken on admission and 4 hours after the subcutaneous injection of third dose of 1mg/kg enoxaparin to the patients.
💡
Conclusion & Impact:Conclusion: Tromboelastography method can be used in assessment of efficacy of enoxaparin in patients with acute coronary syndrome without ST-Segment elevation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:enoksoparin · tromboleastogram · akut koroner sendrom

Abstract

Purpose: The aim of this study was to compare anti-factor Xa assay and tromboelastogram in evaluation of efficacy of enoxaparin in patients with acute coronary syndrome without ST-segment elevation. Materials and Methods: Twenty-five patients with acute coronary syndrome were involved. Two blood samples were taken on admission and 4 hours after the subcutaneous injection of third dose of 1mg/kg enoxaparin to the patients. AntiFXa, tromboelastogram, activated coagulation time were calculated. Results: A non-significant increase in activated coagulation time was observed after the injection of enoxaparin. After injection enoxaparin thromboelastography parameters changed maximum amplitude(MA) increased (MA basal 65.4±11.9 after 63.4±7.8), R time increased (from 5±1.7 to 8.4±4.6,), K time increased (from 1.89±1.06 to 2.56±1.4), angle increased (from 66.34±5.6 to 57.9±11.4). AntiFXa increased. (from 0.122±0.06 to 0.501±0.359). Conclusion: Tromboelastography method can be used in assessment of efficacy of enoxaparin in patients with acute coronary syndrome without ST-Segment elevation.

Özet

Amaç: Tromboelastogram parametrelerindeki değişiklerin standart olarak önerilen AntiFXa aktivitesi ile karşılaştırılarak bu testin enoksaparin tedavisinin monitörizasyonundaki rolünün incelenmesidir. Gereç ve Yöntem: ST segment yükselmesi olmayan miyokard infarktüsü tanısıyla koroner yoğun bakım ünitesine yatırılan 25 hasta çalışmaya alınmıştır. Hastalara yatış anında iki tüp kan alınmış ve 1mg/kg enoksapirinin üçüncü dozu yapıldıktan 4 saat sonra iki tüp kan daha alınmıştır. Hastalara AntiFXa, tromboelastogram, aktive koagülasyon zamanı bakılmıştır. Bulgular: Enoksoparin uygulaması sonrası aktive koagülasyon zamanı değerinde bir miktar artış izlenmekle birlikte bunun anlamlı olmadığı görüldü (p₌0.094). Enoksoparin sonrası tromboelastogram parametrelerinden maksimum amplitüde(MA) azalmış (MA bazal 65.4±11.9 sonra 63.4±7.8), R zamanı artmış (5±1.7 den 8.4±4.6,), K zamanı artmış (1.89±1.06 dan 2.56±1.4), açı azalmıştır. (66.34±5.6 dan 57.9±11.4). AntiFXa artmıştır (0.122±0.06 dan 0.501±0.359). Sonuç: Tromboelastogram parametreleri değerlendirildiğinde tipik artmış bir prokoagülan aktivite olmamakla birlikte kısmen artmış bir fibrinolitik aktivite saptanmıştır.

🔖

Cite This Article

GÜNDÜZ, R., YİLDİZ, B. S., ÖZDEMIR, İ. H., ÖZEN, M. B., ÇETIN, N., YAVUZGİL, O. (2021). Comparison of anti-factorXa assay and rotational thromboelastogram in evaluating the efficacy of enoxaparine treatment in patients with acute coronary syndrome without ST- segment elevation. Cukurova Medical Journal, Cilt: 46 - Sayı: 4, 1478–1484. https://ajindex.com/articles/407108

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Laposata M, Green K, Elisabeth MJAPLM. College of American Pathologist Conference XXXI on laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122:799- 807
  2. Handeland G, Abildgaard U, Holm H, Arnesen KJEjocp. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol. 1990;39:107-12
  3. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux J, Kher A, Aiach M, Fiessinger J, Thrombosis F-SGJ, haemostasis. Adjusted versus fixed doses of the lowmolecular-weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost. 1994;72:698-702
  4. Boneu BJT, haemostasis. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost. 1994;72:330-4
  5. Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A et al. Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate? Thromb Res. 2007;120:347-51
  6. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999-3054
  7. Luddington RJC, Haematology L. Thrombelastography/thromboelastometry. Clin Lab Haematol. 2005;27:81-90
  8. Hirsh J, Raschke RJC. Heparin and low-molecularweight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:188-203
  9. Ibanez B, James S, Agewall S, Antunes MJ, BucciarelliDucci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-77
  10. Linkins L-A, Julian JA, Rischke J, Hirsh J, Weitz JIJTr. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res. 2002;107:241-44
  11. Antman EM, Morrow DA, McCabe CH, Jiang F, White HD, Fox K et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design a